Solventum Corp Q4 FY2024 earnings call

Management Statement and Operational Highlights:

• Transformation Phases: Progressed through three phases of transformation. Phase 1 focused on establishing foundation and business performance turnaround. Phase 2 involves developing a long-term strategic plan, with the long-range strategy to be unveiled at the March 20 Investor Day. Phase 3 is about portfolio optimization, with the divestiture of Purification & Filtration to Thermo Fisher as part of this phase.
• Separation and Restructuring: Separation is on track with 1/4 of transition service agreements exited, ERP systems implemented in six countries, a new plant in Brazil under construction, and a European distribution center cutover planned. Public company stand-up costs and growth investments are driving operating expenses, but savings from restructuring will start in Q1 2025.

Segment Performance:

• MedSurg: Delivered $1.2 billion of sales, an increase of 1.8% on an organic basis. Growth led by higher OEM and advanced wound care, with the V.A.C. Peel and Place dressing driving progress.
• Dental: Generated $315 million of revenue, an increase of 4.2% on an organic basis. Positive response to the Q4 launch of the 3D printed Clarity Precision Grip attachment, with products like Clinpro Clear Fluoride Treatment continuing to resonate.
• Health Information Systems: Contributed $336 million of revenue, an increase of 1.1% on an organic basis. Focus on autonomous coding payment models, with the team believing 50%-90% of cases could be automated via AI-driven technology.
• Purification & Filtration: Delivered $235 million of sales, an increase of 3.5% on an organic basis, fueled by strength in bioprocessing filtration and industrial filtration.

Guidance:

• Organic sales growth expected to be 1%-2% (net of 50 basis point SKU exit impact), with normalized growth of 1.5%-2.5%.
• Operating margin targeted between 20% and 21%.
• EPS guidance range of $5.45 to $5.65.
• Free cash flow guidance in the range of $450 million to $550 million, considering CapEx and interest expenses. Q1 expected to be the low point for margins and EPS, with improvement later in the year.

Risks:

• Separation Milestones: Risk associated with remaining separation milestones in 2025 and 2026, including large ERP implementations and manufacturing transfers.
• Tariffs: Uncertainty around tariff impacts due to dynamic trade environment, with limited exposure but potential impact on manufacturing and sales.
• ERP and Distribution: Risks related to successful ERP cutovers and distribution center transitions, which could disrupt operations if not managed properly.

Question and Answer: Q: Jason Bednar asked about organic growth by segment and free cash flow guidance.

A: Wayde McMillan stated no segment-level guidance but emphasized initiatives cut across all segments, and free cash flow guidance is affected by separation costs and CapEx. Bryan Hanson mentioned the Investor Day will provide more segment-specific color.

Q: Patrick Wood inquired about M&A timeline and operating margin guide.

A: Bryan Hanson said the P&F divestiture moves up M&A timeline, with capacity built to handle tuck-in acquisitions, targeting early 2026. Wayde McMillan explained operating margin guide includes annualizing separation costs and restructuring savings.

Q: David Roman asked about end markets and market outlook.

A: Bryan Hanson noted Dental's growth was partially due to comps, with more details on end markets to be provided at the Investor Day.

Q: Travis Steed questioned operating margin guide and P&F divestiture EPS impact.

A: Wayde McMillan explained operating margin guide factors in separation costs and restructuring, and the P&F divestiture is expected to be EPS neutral in 2025 due to timing of deal close and debt tender.

Q: Vikramjeet Chopra asked about tariffs and dividend/buyback plans.

A: Wayde McMillan discussed limited tariff exposure and manufacturing locations, while Bryan Hanson stated proceeds from P&F divestiture will be used to repay debt, with no immediate plans for dividends or buybacks due to 3M agreement restrictions.